In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fleming stock, debt offering

This article was originally published in The Rose Sheet

Executive Summary

Texas-based consumer product distributor announces offering of 8 mil. shares of common stock and $200 mil. in senior notes, with estimated net proceeds of $385 mil. Proceeds will be used to fund the firm's $390 mil. purchase of Core-Mark International, a "piece-pick" distributor to convenience stores operating primarily in western North America. With the acquisition, Fleming's total annualized sales will top $19 mil. Fleming recently announced a nearly $20 mil. fourth quarter charge related to the Kmart bankruptcy (1"The Rose Sheet" Feb. 18, 2002, In Brief)...

You may also be interested in...

Fleming takes fourth quarter charge

Distributor Fleming Companies records $19.8 mil. pre-tax charge in fourth quarter related to Kmart bankruptcy reorganization, company says. Charge "represents reserves against Fleming's total $37.8 mil. in pre-petition receivables from Kmart and against certain slow-moving Kmart-related inventory," Fleming adds, noting it intends to pursue collection of all money it is owed through bankruptcy court. Distribution segment sales increased 31% in the quarter on a 12-week comparable basis, and earnings before interest, taxes, depreciation and amortization were up 20% to $137.9 mil. Fleming is exclusive foods and consumable goods distributor to Kmart and distributes for Procter & Gamble and Dial among others. Kmart filed for bankruptcy in January (1"The Rose Sheet" Jan. 28, 2002, p. 7)...

Reckitt Targets UK's Painful ‘Tweens’ With Double-Strength Nurofen

Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."

Novartis’s New Eye Treatment Beovu Gets CHMP Nod

Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts